Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $11.75.

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. HC Wainwright increased their price target on shares of Regulus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. StockNews.com assumed coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They issued a “sell” rating for the company. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. Finally, SVB Leerink initiated coverage on Regulus Therapeutics in a report on Monday, March 18th. They set an “outperform” rating and a $6.00 price target on the stock.

Regulus Therapeutics Trading Down 7.4 %

RGLS stock opened at $1.76 on Wednesday. The firm has a 50 day moving average price of $2.22 and a 200-day moving average price of $1.93. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.14). Research analysts predict that Regulus Therapeutics will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in RGLS. Victory Capital Management Inc. boosted its stake in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after buying an additional 38,529 shares during the last quarter. Opaleye Management Inc. purchased a new position in Regulus Therapeutics in the first quarter worth about $490,000. Vanguard Group Inc. grew its stake in shares of Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares during the period. FMR LLC increased its position in shares of Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 716,000 shares during the last quarter. Finally, CVI Holdings LLC bought a new position in shares of Regulus Therapeutics in the 1st quarter worth approximately $4,050,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.